Puma Biotechnology (PBYI) Competitors $3.35 -0.28 (-7.71%) Closing price 04:00 PM EasternExtended Trading$3.34 0.00 (-0.15%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. BCYC, ANAB, COGT, VECT, SION, KROS, IMTX, TYRA, VALN, and MRVIShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Cogent Biosciences (COGT), VectivBio (VECT), Sionna Therapeutics (SION), Keros Therapeutics (KROS), Immatics (IMTX), Tyra Biosciences (TYRA), Valneva (VALN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Bicycle Therapeutics AnaptysBio Cogent Biosciences VectivBio Sionna Therapeutics Keros Therapeutics Immatics Tyra Biosciences Valneva Maravai LifeSciences Puma Biotechnology (NASDAQ:PBYI) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Does the MarketBeat Community prefer PBYI or BCYC? Puma Biotechnology received 412 more outperform votes than Bicycle Therapeutics when rated by MarketBeat users. However, 70.53% of users gave Bicycle Therapeutics an outperform vote while only 67.39% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55867.39% Underperform Votes27032.61% Bicycle TherapeuticsOutperform Votes14670.53% Underperform Votes6129.47% Do analysts prefer PBYI or BCYC? Puma Biotechnology currently has a consensus target price of $7.00, suggesting a potential upside of 108.96%. Bicycle Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 210.56%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has stronger valuation & earnings, PBYI or BCYC? Puma Biotechnology has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$232.71M0.71$21.59M$0.774.35Bicycle Therapeutics$25.72M21.67-$180.66M-$3.14-2.56 Is PBYI or BCYC more profitable? Puma Biotechnology has a net margin of 9.56% compared to Bicycle Therapeutics' net margin of -450.64%. Puma Biotechnology's return on equity of 41.60% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Bicycle Therapeutics -450.64%-27.35%-20.81% Which has more volatility and risk, PBYI or BCYC? Puma Biotechnology has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Do insiders & institutionals believe in PBYI or BCYC? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to PBYI or BCYC? In the previous week, Bicycle Therapeutics had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Bicycle Therapeutics and 2 mentions for Puma Biotechnology. Bicycle Therapeutics' average media sentiment score of 0.82 beat Puma Biotechnology's score of 0.54 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPuma Biotechnology beats Bicycle Therapeutics on 10 of the 18 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.26M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio6.988.9226.8419.71Price / Sales0.71250.96391.39116.98Price / Cash4.1965.8538.2534.62Price / Book2.996.466.794.50Net Income$21.59M$143.98M$3.23B$248.18M7 Day Performance15.52%3.04%4.07%1.14%1 Month Performance17.13%7.44%12.52%15.18%1 Year Performance-19.66%-2.46%16.83%6.55% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.5583 of 5 stars$3.35-7.7%$7.00+109.0%-16.9%$166.26M$232.71M6.98200BCYCBicycle Therapeutics3.8017 of 5 stars$8.60+3.1%$25.00+190.7%-60.8%$595.14M$25.72M-2.61240Gap UpANABAnaptysBio3.3459 of 5 stars$20.03+2.2%$35.88+79.1%-15.6%$588.48M$111.87M-3.29100Positive NewsGap DownCOGTCogent Biosciences2.3651 of 5 stars$5.13+6.7%$14.29+178.5%-32.3%$584.08MN/A-2.0780News CoveragePositive NewsAnalyst ForecastGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeSIONSionna TherapeuticsN/A$12.90+4.7%$38.50+198.4%N/A$569.20MN/A0.0035KROSKeros Therapeutics3.2551 of 5 stars$13.74+0.7%$37.00+169.3%-73.0%$558.05M$214.71M-2.64100Positive NewsIMTXImmatics2.8315 of 5 stars$4.56+7.5%$16.67+265.5%-50.6%$554.27M$155.84M-6.91260News CoveragePositive NewsTYRATyra Biosciences1.7063 of 5 stars$10.26+1.7%$30.83+200.5%-46.7%$544.70MN/A-6.3720News CoveragePositive NewsAnalyst ForecastAnalyst RevisionVALNValneva2.1442 of 5 stars$6.45-0.3%$15.50+140.3%-27.5%$539.45M$169.58M-49.62700MRVIMaravai LifeSciences4.083 of 5 stars$2.12+7.1%$6.34+199.2%-78.8%$539.19M$259.19M-1.29610Gap Up Related Companies and Tools Related Companies Bicycle Therapeutics Competitors AnaptysBio Competitors Cogent Biosciences Competitors VectivBio Competitors Sionna Therapeutics Competitors Keros Therapeutics Competitors Immatics Competitors Tyra Biosciences Competitors Valneva Competitors Maravai LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
